表皮生长因子受体（EGFR）突变的腺鳞癌中因T790M阳性鳞状进展导致对阿法替尼获得性耐药 - Suppr

Acquired Resistance to Afatinib Due to T790M-Positive Squamous Progression in EGFR-Mutant Adenosquamous Lung Carcinoma.

作者信息

Ricciuti Biagio, Metro Giulio, Brambilla Marta, Ludovini Vienna, Baglivo Sara, Siggillino Annamaria, Prosperi Enrico, Chiari Rita

机构信息

Medical Oncology, Santa Maria della Misericordia Hospital, University of Perugia, Perugia, Italy.

出版信息

J Thorac Oncol. 2018 Jan;13(1):e9-e12. doi: 10.1016/j.jtho.2017.08.025.

DOI:10.1016/j.jtho.2017.08.025

PMID:29258673

Abstract

摘要

相似文献

Acquired Resistance to Afatinib Due to T790M-Positive Squamous Progression in EGFR-Mutant Adenosquamous Lung Carcinoma.表皮生长因子受体（EGFR）突变的腺鳞癌中因T790M阳性鳞状进展导致对阿法替尼获得性耐药

J Thorac Oncol. 2018 Jan;13(1):e9-e12. doi: 10.1016/j.jtho.2017.08.025.

Afatinib and Erlotinib in the treatment of squamous-cell lung cancer.阿法替尼和厄洛替尼治疗鳞状细胞肺癌。

Expert Opin Pharmacother. 2018 Dec;19(18):2055-2062. doi: 10.1080/14656566.2018.1540591. Epub 2018 Nov 3.

Palbociclib overcomes afatinib resistance in non-small cell lung cancer.帕博西尼克服非小细胞肺癌对阿法替尼的耐药性。

Biomed Pharmacother. 2019 Jan;109:1750-1757. doi: 10.1016/j.biopha.2018.10.170. Epub 2018 Nov 21.

Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial.阿法替尼对比厄洛替尼二线治疗晚期肺鳞癌患者（LUX-Lung 8）：一项开放标签、随机对照、III 期临床研究。

Lancet Oncol. 2015 Aug;16(8):897-907. doi: 10.1016/S1470-2045(15)00006-6. Epub 2015 Jul 5.

Activity of the EGFR-HER2 dual inhibitor afatinib in EGFR-mutant lung cancer patients with acquired resistance to reversible EGFR tyrosine kinase inhibitors.表皮生长因子受体-人表皮生长因子受体2（EGFR-HER2）双重抑制剂阿法替尼在对可逆性EGFR酪氨酸激酶抑制剂产生获得性耐药的EGFR突变肺癌患者中的活性。

Clin Lung Cancer. 2014 Nov;15(6):411-417.e4. doi: 10.1016/j.cllc.2014.07.002. Epub 2014 Aug 16.

Overall survival in EGFR mutated non-small-cell lung cancer patients treated with afatinib after EGFR TKI and resistant mechanisms upon disease progression.表皮生长因子受体（EGFR）酪氨酸激酶抑制剂（TKI）治疗后接受阿法替尼治疗的EGFR突变型非小细胞肺癌患者的总生存期及疾病进展时的耐药机制

PLoS One. 2017 Aug 30;12(8):e0182885. doi: 10.1371/journal.pone.0182885. eCollection 2017.

Cost-effectiveness of afatinib and erlotinib as second-line treatments for advanced squamous cell carcinoma of the lung.阿法替尼与厄洛替尼二线治疗晚期肺鳞癌的成本效果分析。

Future Oncol. 2018 Nov;14(27):2833-2840. doi: 10.2217/fon-2018-0321. Epub 2018 Jun 7.

Clinical implications of T790M mutation in patients with acquired resistance to EGFR tyrosine kinase inhibitors.表皮生长因子受体酪氨酸激酶抑制剂获得性耐药患者 T790M 突变的临床意义。

Lung Cancer. 2013 Nov;82(2):294-8. doi: 10.1016/j.lungcan.2013.08.023. Epub 2013 Sep 3.

Miliary Adenocarcinoma of the Lung Responds to Gefitinib and Afatinib.肺粟粒性腺癌对吉非替尼和阿法替尼有反应。

J Thorac Oncol. 2018 Jun;13(6):e95-e97. doi: 10.1016/j.jtho.2018.01.018.

Acquired Resistance to First-Line Afatinib and the Challenges of Prearranged Progression Biopsies.获得性对一线阿法替尼耐药和预先安排进展活检的挑战。

J Thorac Oncol. 2016 Nov;11(11):2022-2026. doi: 10.1016/j.jtho.2016.06.032. Epub 2016 Aug 20.

引用本文的文献

Lineage Plasticity in Cancer: The Tale of a Skin-Walker.癌症中的谱系可塑性：一个易形者的故事。

Cancers (Basel). 2021 Jul 18;13(14):3602. doi: 10.3390/cancers13143602.

Retroperitoneal Metastasis, with Marked Fibrosis, of Lung Adenocarcinoma after Afatinib Treatment: An Autopsy Case Report.阿法替尼治疗后肺腺癌伴显著纤维化的腹膜后转移：尸检病例报告。

Intern Med. 2020 Nov 15;59(22):2915-2919. doi: 10.2169/internalmedicine.4869-20. Epub 2020 Jul 28.

Understanding Lineage Plasticity as a Path to Targeted Therapy Failure in -Mutant Non-small Cell Lung Cancer.理解谱系可塑性作为KRAS突变型非小细胞肺癌靶向治疗失败的一条途径

Front Genet. 2020 Mar 27;11:281. doi: 10.3389/fgene.2020.00281. eCollection 2020.

Adenosquamous carcinoma of the lung.肺腺鳞癌

Onco Targets Ther. 2018 Aug 14;11:4829-4835. doi: 10.2147/OTT.S164574. eCollection 2018.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Acquired Resistance to Afatinib Due to T790M-Positive Squamous Progression in EGFR-Mutant Adenosquamous Lung Carcinoma.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献检索

文件翻译

深度研究

Suppr 超能文献

相似文献

引用本文的文献